You must be logged in to cast votes
usually most pronounced during dose escalation Diarrhea : Affects 12-17% of patients, typically mild to moderate in severity Vomiting : Reported in 6-10% of patients, more common at higher doses Constipation : Occurs in 6-11% of patients Abdominal pain and dyspepsia : Generally transient Decreased appetite : An expected pharmacological effect contributing to weight loss Other documented adverse effects include injection site reactions, hypoglycemia (when used with insulin or sulfonylureas), and less commonly, fatigue
Metastasis 33 (4), 385399
Having a spacer with a chain length of about 16 carbons was the right compromise
Online TB-500 peptide products may carry risks related to purity, contamination, inconsistent dosing, and unclear long-term safety
Give the receptor a brake: Slowing gastric emptying by GLP-1